Acute Metabolic Effects of LAF 237 in Type 2 Diabetics
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
Incretin hormones (GIP and GLP-1) stimulate insulin release in a glucose dependant manner,
hence are necessary for maintenance of normal glucose tolerance. Both GIP and GLP-1 are
degraded and inactivated by DPP-4.
LAF 237 is an inhibitor of DPP-4 that has been shown to increase meal-stimulated levels of
intact GLP-1 in animals and patients with T2DM..
The purpose of the current study is to explore the acute effects of LAF237 on the rate of
appearance and disappearance of glucose in type 2 diabetics. Secondary objectives include the
effect on FPG, insulin secretion rates, glucagon and FFA levels, and rate of glucose entry
from the GI tract.
Phase:
Phase 3
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio